orchard therapeutics (europe) limited
orchard therapeutics (europe) limited Company Information
Company Number
09759506
Website
www.orchard-tx.comRegistered Address
245 hammersmith road, 3rd floor, london, W6 8PW
Industry
Research and experimental development on biotechnology
Telephone
02038088286
Next Accounts Due
September 2024
Group Structure
View All
Directors
Hubert Gaspar8 Years
Shareholders
orchard therapeutics plc 100%
orchard therapeutics (europe) limited Estimated Valuation
Pomanda estimates the enterprise value of ORCHARD THERAPEUTICS (EUROPE) LIMITED at £33.9m based on a Turnover of £18.2m and 1.86x industry multiple (adjusted for size and gross margin).
orchard therapeutics (europe) limited Estimated Valuation
Pomanda estimates the enterprise value of ORCHARD THERAPEUTICS (EUROPE) LIMITED at £0 based on an EBITDA of £-99.2m and a 7.86x industry multiple (adjusted for size and gross margin).
orchard therapeutics (europe) limited Estimated Valuation
Pomanda estimates the enterprise value of ORCHARD THERAPEUTICS (EUROPE) LIMITED at £0 based on Net Assets of £-171.2m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Orchard Therapeutics (europe) Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Orchard Therapeutics (europe) Limited Overview
Orchard Therapeutics (europe) Limited is a live company located in london, W6 8PW with a Companies House number of 09759506. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in September 2015, it's largest shareholder is orchard therapeutics plc with a 100% stake. Orchard Therapeutics (europe) Limited is a young, mid sized company, Pomanda has estimated its turnover at £18.2m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Orchard Therapeutics (europe) Limited Health Check
Pomanda's financial health check has awarded Orchard Therapeutics (Europe) Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 6 areas for improvement. Company Health Check FAQs
5 Strong
1 Regular
6 Weak
Size
annual sales of £18.2m, make it larger than the average company (£3.5m)
£18.2m - Orchard Therapeutics (europe) Limited
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 109%, show it is growing at a faster rate (14.1%)
109% - Orchard Therapeutics (europe) Limited
14.1% - Industry AVG
Production
with a gross margin of 71%, this company has a lower cost of product (53%)
71% - Orchard Therapeutics (europe) Limited
53% - Industry AVG
Profitability
an operating margin of -589.9% make it less profitable than the average company (-0.4%)
-589.9% - Orchard Therapeutics (europe) Limited
-0.4% - Industry AVG
Employees
with 139 employees, this is above the industry average (44)
139 - Orchard Therapeutics (europe) Limited
44 - Industry AVG
Pay Structure
on an average salary of £172.6k, the company has a higher pay structure (£77.9k)
£172.6k - Orchard Therapeutics (europe) Limited
£77.9k - Industry AVG
Efficiency
resulting in sales per employee of £131.2k, this is equally as efficient (£136.2k)
£131.2k - Orchard Therapeutics (europe) Limited
£136.2k - Industry AVG
Debtor Days
it gets paid by customers after 140 days, this is later than average (51 days)
140 days - Orchard Therapeutics (europe) Limited
51 days - Industry AVG
Creditor Days
its suppliers are paid after 455 days, this is slower than average (70 days)
455 days - Orchard Therapeutics (europe) Limited
70 days - Industry AVG
Stock Days
it holds stock equivalent to 194 days, this is more than average (48 days)
194 days - Orchard Therapeutics (europe) Limited
48 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 4 weeks, this is less cash available to meet short term requirements (35 weeks)
4 weeks - Orchard Therapeutics (europe) Limited
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 303%, this is a higher level of debt than the average (50%)
303% - Orchard Therapeutics (europe) Limited
50% - Industry AVG
orchard therapeutics (europe) limited Credit Report and Business Information
Orchard Therapeutics (europe) Limited Competitor Analysis
Perform a competitor analysis for orchard therapeutics (europe) limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
orchard therapeutics (europe) limited Ownership
ORCHARD THERAPEUTICS (EUROPE) LIMITED group structure
Orchard Therapeutics (Europe) Limited has no subsidiary companies.
Ultimate parent company
KIRIN HOLDINGS CO LTD
#0097043
2 parents
ORCHARD THERAPEUTICS (EUROPE) LIMITED
09759506
orchard therapeutics (europe) limited directors
Orchard Therapeutics (Europe) Limited currently has 1 director, Dr Hubert Gaspar serving since Feb 2016.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Hubert Gaspar | England | 60 years | Feb 2016 | - | Director |
ORCHARD THERAPEUTICS (EUROPE) LIMITED financials
Orchard Therapeutics (Europe) Limited's latest turnover from December 2022 is £18.2 million and the company has net assets of -£171.2 million. According to their latest financial statements, Orchard Therapeutics (Europe) Limited has 139 employees and maintains cash reserves of £20.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|
| Turnover | 18,231,215 | 1,228,133 | 2,027,782 | 2,000,810 | 1,590,146 | 0 | |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost Of Sales | 5,279,677 | 164,335 | 669,929 | 640,583 | 499,081 | 0 | |
| Gross Profit | 12,951,538 | 1,063,798 | 1,357,853 | 1,360,227 | 1,091,065 | 0 | |
| Admin Expenses | 120,490,183 | 153,050,525 | 151,653,505 | 146,960,155 | 92,313,503 | 29,626,969 | |
| Operating Profit | -107,538,645 | -151,986,727 | -150,295,652 | -145,599,928 | -91,222,438 | -29,626,969 | |
| Interest Payable | 16,966,070 | 1,022,210 | 0 | 0 | 0 | 0 | |
| Interest Receivable | 0 | 0 | 1,901,417 | 2,677,288 | 296,091 | 0 | |
| Pre-Tax Profit | -124,504,715 | -153,008,937 | -148,394,235 | -142,922,640 | -86,380,387 | -30,221,061 | |
| Tax | 4,690,504 | 9,909,223 | 17,203,204 | 11,316,044 | 7,697,720 | 0 | |
| Profit After Tax | -119,814,211 | -143,099,714 | -131,191,031 | -131,606,596 | -78,682,667 | -30,221,061 | |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | -119,814,211 | -143,099,714 | -131,191,031 | -131,606,596 | -78,682,667 | -30,221,061 | |
| Employee Costs | 23,996,516 | 28,259,933 | 29,251,109 | 19,462,599 | 10,665,921 | 3,769,939 | |
| Number Of Employees | 139 | 146 | 117 | 95 | 41 | 17 | 9 |
| EBITDA* | -99,207,927 | -108,880,715 | -136,470,373 | -134,133,369 | -83,486,334 | -29,585,407 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|
| Tangible Assets | 6,164,485 | 2,652,390 | 2,690,357 | 1,944,232 | 1,338,227 | 407,087 | 161,348 |
| Intangible Assets | 38,729,492 | 45,692,317 | 87,999,928 | 97,437,763 | 93,400,587 | 5,670,706 | 8,856,775 |
| Investments & Other | 692 | 692 | 692 | 692 | 692 | 691 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 44,894,669 | 48,345,399 | 90,690,977 | 99,382,687 | 94,739,506 | 6,078,484 | 9,018,123 |
| Stock & work in progress | 2,809,408 | 1,493,438 | 487,101 | 0 | 0 | 0 | 0 |
| Trade Debtors | 6,995,445 | 1,096,604 | 643,088 | 1,098,888 | 1,657,447 | 902,843 | 0 |
| Group Debtors | 0 | 0 | 0 | 20,888 | 28,664,535 | 0 | 261,715 |
| Misc Debtors | 9,305,898 | 27,634,967 | 16,710,947 | 25,051,748 | 12,790,490 | 2,227,760 | 90,127 |
| Cash | 20,342,094 | 5,302,506 | 19,122,681 | 3,056,691 | 100,193,983 | 66,159,462 | 2,856,342 |
| misc current assets | 0 | 0 | 0 | 58,164,424 | 0 | 0 | 0 |
| total current assets | 39,452,845 | 35,527,515 | 36,963,817 | 87,392,639 | 143,306,455 | 69,290,065 | 3,208,184 |
| total assets | 84,347,514 | 83,872,914 | 127,654,794 | 186,775,326 | 238,045,961 | 75,368,549 | 12,226,307 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 6,583,926 | 6,328,069 | 5,700,580 | 5,733,305 | 13,035,185 | 2,084,676 | 399,160 |
| Group/Directors Accounts | 214,959,527 | 110,832,335 | 28,789,628 | 110,856,756 | 28,402,982 | 129,304 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 18,567,015 | 11,721,449 | 13,764,857 | 16,841,095 | 14,093,970 | 4,087,422 | 694,314 |
| total current liabilities | 240,110,468 | 128,881,853 | 48,255,065 | 133,431,156 | 55,532,137 | 6,301,402 | 1,093,474 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 11,005,148 | 9,275,065 | 0 | 444,317 | 437,609 | 0 | 0 |
| provisions | 4,439,472 | 2,850,149 | 3,598,393 | 5,176,313 | 8,147,743 | 0 | 0 |
| total long term liabilities | 15,444,620 | 12,125,214 | 3,598,393 | 5,620,630 | 8,585,352 | 0 | 0 |
| total liabilities | 255,555,088 | 141,007,067 | 51,853,458 | 139,051,786 | 64,117,489 | 6,301,402 | 1,093,474 |
| net assets | -171,207,574 | -57,134,153 | 75,801,336 | 47,723,540 | 173,928,472 | 69,067,147 | 11,132,833 |
| total shareholders funds | -171,207,574 | -57,134,153 | 75,801,336 | 47,723,540 | 173,928,472 | 69,067,147 | 11,132,833 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Profit | -107,538,645 | -151,986,727 | -150,295,652 | -145,599,928 | -91,222,438 | -29,626,969 | |
| Depreciation | 1,367,893 | 1,184,701 | 717,458 | 415,730 | 227,570 | 41,562 | 4,640 |
| Amortisation | 6,962,825 | 41,921,311 | 13,107,821 | 11,050,829 | 7,508,534 | 0 | 437,540 |
| Tax | 4,690,504 | 9,909,223 | 17,203,204 | 11,316,044 | 7,697,720 | 0 | |
| Stock | 1,315,970 | 1,006,337 | 487,101 | 0 | 0 | 0 | 0 |
| Debtors | -12,430,228 | 11,377,536 | -8,817,489 | -16,940,948 | 39,981,869 | 2,778,761 | 351,842 |
| Creditors | 255,857 | 627,489 | -32,725 | -7,301,880 | 10,950,509 | 1,685,516 | 399,160 |
| Accruals and Deferred Income | 6,845,566 | -2,043,408 | -3,076,238 | 2,747,125 | 10,006,548 | 3,393,108 | 694,314 |
| Deferred Taxes & Provisions | 1,589,323 | -748,244 | -1,577,920 | -2,971,430 | 8,147,743 | 0 | 0 |
| Cash flow from operations | -74,712,419 | -113,519,528 | -115,623,664 | -113,402,562 | -86,665,683 | -27,285,544 | |
| Investing Activities | |||||||
| capital expenditure | |||||||
| Change in Investments | 0 | 0 | 0 | 0 | 1 | 691 | 0 |
| cash flow from investments | |||||||
| Financing Activities | |||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 104,127,192 | 82,042,707 | -82,067,128 | 82,453,774 | 28,273,678 | 129,304 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 1,730,083 | 9,275,065 | -444,317 | 6,708 | 437,609 | 0 | 0 |
| share issue | |||||||
| interest | -16,966,070 | -1,022,210 | 1,901,417 | 2,677,288 | 296,091 | 0 | |
| cash flow from financing | 94,631,995 | 100,459,787 | 78,658,799 | 90,539,434 | 212,551,370 | 88,284,679 | |
| cash and cash equivalents | |||||||
| cash | 15,039,588 | -13,820,175 | 16,065,990 | -97,137,292 | 34,034,521 | 63,303,120 | 2,856,342 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 15,039,588 | -13,820,175 | 16,065,990 | -97,137,292 | 34,034,521 | 63,303,120 | 2,856,342 |
P&L
December 2022turnover
18.2m
+1384%
operating profit
-107.5m
-29%
gross margin
71.1%
-17.99%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
-171.2m
+2%
total assets
84.3m
+0.01%
cash
20.3m
+2.84%
net assets
Total assets minus all liabilities
orchard therapeutics (europe) limited company details
company number
09759506
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
September 2015
age
9
accounts
Audit Exemption Subsidiary
ultimate parent company
previous names
orchard therapeutics limited (October 2018)
newincco 1387 limited (November 2015)
incorporated
UK
address
245 hammersmith road, 3rd floor, london, W6 8PW
last accounts submitted
December 2022
orchard therapeutics (europe) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to orchard therapeutics (europe) limited. Currently there are 2 open charges and 1 have been satisfied in the past.
orchard therapeutics (europe) limited Companies House Filings - See Documents
| date | description | view/download |
|---|
